GlassScriptPhysician profile
Eva L Bartlett
NPI 1912044215
$2,165.39
in general payments reported to CMS, 2019-2025
28 companies · $793 in 2025
The $793 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.45 · 2021: $22.73 · 2022: $81.53 · 2023: $321 · 2024: $868 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.69 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $296.87 | 2023-2025 | |
| Novo Nordisk INC | $242.43 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $204.99 | 2023-2025 | Veozah |
| Lilly USA, LLC | $133.10 | 2021-2024 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $115.95 | 2023-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $111.05 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.22 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $90.95 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $83.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Indivior INC. | $81.32 | 2024-2025 | Sublocade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.10 | 2019-2025 | Jardiance |
| Pfizer INC. | $73.02 | 2019-2024 | |
| Mylan Specialty L.P. | $69.82 | 2024 | Yupelri |
| Supernus Pharmaceuticals, INC. | $65.55 | 2019-2025 | Qelbree, Xyosted |
| Vanda Pharmaceuticals INC. | $52.37 | 2025 | Fanapt |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $50.98 | 2023-2025 | Dexcom G6 Transmitter |
| Orexo US, INC. | $40.08 | 2022 | |
| Eisai INC. | $36.24 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $36.20 | 2023-2024 | Eliquis |
| Antares Pharma, INC. | $34.01 | 2024-2025 | Xyosted |
| Viatris Specialty LLC | $28.21 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $24.78 | 2024 | Spravato |
| Alkermes, INC. | $24.29 | 2024 | Vivitrol |
| Glaxosmithkline, LLC. | $21.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.56 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $17.91 | 2025 | Rexulti |
| Halozyme INC | $15.89 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Bartlett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.